STOCK TITAN

Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Vertex Pharmaceuticals (Nasdaq: VRTX) will present at the Jefferies Virtual London Health Care Conference on November 19, 2020, at 9:05 a.m. ET. The audio from this presentation will be available live on Vertex's website in the 'Investors' section. The company is known for its innovative approach to treating serious diseases, particularly cystic fibrosis, and has a strong pipeline that includes therapies for genetic and cell-related diseases. Vertex has been recognized as a top employer in the biotech industry.

Positive
  • None.
Negative
  • None.

BOSTON--()--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual London Health Care Conference on Thursday, November 19, 2020 at 9:05 a.m. ET (2:05 p.m. GMT).

The audio portion of management's remarks will be available live through Vertex's website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram. (VRTX-WEB)

Contacts

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, 617-341-6108
Zach Barber, 617-341-6470
Brenda Eustace, 617-341-6187

FAQ

When will Vertex Pharmaceuticals present at the Jefferies Virtual London Health Care Conference?

Vertex Pharmaceuticals will present at the Jefferies Virtual London Health Care Conference on November 19, 2020, at 9:05 a.m. ET.

Where can I listen to Vertex Pharmaceuticals' presentation at the Jefferies conference?

The audio of Vertex Pharmaceuticals' presentation will be available live on their website under the 'Investors' section.

What is Vertex Pharmaceuticals known for?

Vertex Pharmaceuticals is known for developing transformative medicines, particularly for cystic fibrosis, and has a robust pipeline of investigational therapies for various serious diseases.

What therapies are included in Vertex's pipeline?

Vertex's pipeline includes therapies for cystic fibrosis, sickle cell disease, beta thalassemia, and Duchenne muscular dystrophy, among others.

What accolades has Vertex Pharmaceuticals received as an employer?

Vertex Pharmaceuticals has been recognized as one of the industry's top places to work, including being on Science magazine's Top Employers list for 11 consecutive years.

Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Stock Data

102.15B
257.08M
0.08%
96.18%
1.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON